Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Quebec Clinical Research Organization in Cancer (Q-CROC), Exactis Innovation and the Segal Cancer Centre, Montreal, QC, Canada.
Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.
Ultrasensitive methods for rare allele detection are critical to leverage the full potential offered by liquid biopsies. Here, we describe a novel molecular barcoding method for the precise detection and quantification of circulating tumor DNA (ctDNA). The major benefits of our design include straightforward and cost-effective production of barcoded adapters to tag individual DNA molecules before PCR and sequencing, and better control over cross-contamination between experiments. We validated our approach in a cohort of 24 patients with a broad spectrum of cancer diagnoses by targeting and quantifying single-nucleotide variants (SNVs), indels and genomic rearrangements in plasma samples. By using personalized panels targeting a priori known mutations, we demonstrate comprehensive error-suppression capabilities for SNVs and detection thresholds for ctDNA below 0.1%. We also show that our semi-degenerate barcoded adapters hold promise for noninvasive genotyping in the absence of tumor biopsies and monitoring of minimal residual disease in longitudinal plasma samples. The benefits demonstrated here include broad applicability, flexibility, affordability and reproducibility in the research and clinical settings.
超敏检测稀有等位基因的方法对于充分利用液体活检的潜力至关重要。在这里,我们描述了一种用于精确检测和定量循环肿瘤 DNA(ctDNA)的新型分子条码方法。我们设计的主要优点包括在 PCR 和测序之前标记单个 DNA 分子的条码适配器的生产简单且具有成本效益,以及更好地控制实验之间的交叉污染。我们通过靶向和定量血浆样本中的单核苷酸变异(SNV)、插入缺失和基因组重排,在一组具有广泛癌症诊断的 24 名患者的队列中验证了我们的方法。通过使用针对先验已知突变的个性化面板,我们证明了 SNV 的全面错误抑制能力和 ctDNA 的检测阈值低于 0.1%。我们还表明,我们的半简并条码适配器具有在没有肿瘤活检的情况下进行无创基因分型和在纵向血浆样本中监测微小残留疾病的潜力。这里展示的优势包括在研究和临床环境中的广泛适用性、灵活性、可负担性和可重复性。